Neurodegeneration risk variants promote lysosomal TMEM106B fibrilaccumulation

This study reveals that neurodegeneration risk variants in *TMEM106B* and *GRN* converge to promote the accumulation of intra-lysosomal TMEM106B fibrils, which drive age-related cognitive decline and neuronal damage through impaired degradation and lysosomal rupture.

The Gist

The Big Picture: The Brain's "Trash Can" Breakdown

Imagine your brain cells are like busy factories. To keep running smoothly, they need to constantly clean up their waste. They have special trash cans inside them called lysosomes. These trash cans break down old proteins and junk so the factory can stay clean.

As we get older, these trash cans start to get clogged and slow down. When they get too full or broken, the junk piles up, and the factory (the brain cell) starts to fail. This is the root of many neurodegenerative diseases like Alzheimer's and Frontotemporal Dementia (FTD).

This paper discovered exactly what is clogging the trash cans and why certain people are more likely to get sick than others.

---

The Main Characters

1. The Trash Can (Lysosome): The recycling center of the cell.
2. The Garbage (TMEM106B): A protein that usually gets broken down by the trash can.
3. The "Super-Glue" (TMEM106B Fibrils): Sometimes, instead of being recycled, pieces of the garbage turn into hard, sticky fibers (like super-glue) that get stuck inside the trash can.
4. The Supervisor (Progranulin/GRN): A protein that acts like a manager, helping the trash can work efficiently.

The Problem: Two Bad Genes Team Up

Scientists have long known that two specific genes, TMEM106B and GRN, are linked to brain diseases. But they didn't know how they worked together.

Think of it like a car with two bad parts:

• The TMEM106B Risk Variant: Imagine this is a piece of garbage that is slightly sticky. It's harder to break down than normal garbage.
• The GRN Risk Variant: Imagine this is a lazy supervisor who doesn't show up to work. Without the supervisor, the trash can works half as fast.

The Discovery:
The paper shows that when you have the "sticky garbage" (TMEM106B risk) AND the "lazy supervisor" (GRN risk), the trash can gets completely overwhelmed. The sticky garbage turns into long, hard fibers (fibrils) that pile up inside the trash can.

The "Sticky Garbage" Experiment

The researchers wanted to prove that these sticky fibers are the actual cause of the damage, not just a side effect.

• The Setup: They created a special model in mouse brains and human cells where they forced the "sticky garbage" (TMEM106B fibrils) to build up inside the trash cans.
• The Result: Just by having these fibers pile up, the cells started to die. The mice developed signs of brain disease, including inflammation and the buildup of other toxic proteins (like TDP-43, which is a hallmark of dementia).
• The Conclusion: The sticky fibers themselves are toxic. They are the "smoking gun" that causes the brain cells to fail.

The "Exploding Trash Can"

Here is the most dramatic part of the discovery.

The researchers used a super-powerful microscope (Cryo-Electron Tomography) to look inside the cells. They saw that the sticky fibers were growing inside the trash can.

Imagine a balloon (the trash can) being filled with hard, sharp sticks (the fibers).

• In normal aging: The sticks grow slowly, and the balloon stretches a bit but holds.
• In disease (especially with the GRN mutation): The sticks grow so fast and so long that they pierce the balloon.

The paper found that in patients with the worst genetic risk, these fibers actually burst through the wall of the trash can, poking out into the rest of the cell. This is like a trash bag ripping open and spilling toxic garbage all over the kitchen floor. This rupture kills the cell and spreads the damage to neighbors.

The Good News: A Potential Fix

The paper also tested a "rescue" mission. They added extra Progranulin (the Supervisor) to the cells.

• The Result: When they added the supervisor, the sticky garbage was cleaned up almost instantly. The fibers disappeared.
• The Takeaway: This suggests that treatments designed to boost levels of Progranulin (which are already in clinical trials) might work by helping the brain clear out these sticky fibers before they can clog the trash cans and burst them.

Summary in a Nutshell

1. The Cause: Two common genetic risks (TMEM106B and GRN) work together to slow down the brain's recycling system.
2. The Mechanism: This causes a specific protein to turn into hard, sticky fibers that get trapped inside the cell's trash cans.
3. The Damage: These fibers grow so large they rip the trash can open, spilling toxic waste and killing the brain cell.
4. The Hope: Boosting the "supervisor" protein (Progranulin) can clear these fibers, offering a promising path to treat or prevent these diseases.

Essentially, the brain isn't just getting old; it's getting clogged with a specific type of "super-sticky" trash that breaks the recycling bins. Fixing the recycling process could stop the brain from breaking down.

Technical Summary

1. Problem Statement

Neurodegenerative diseases, including Frontotemporal Lobar Degeneration (FTLD), Alzheimer's Disease (AD), and Parkinson's Disease, are strongly linked to genetic variants in lysosomal genes, specifically TMEM106B and GRN (encoding progranulin).

• The Genetic Puzzle: While it is known that GRN loss-of-function mutations and TMEM106B risk haplotypes interact to increase disease risk and modify age of onset, the molecular mechanism connecting these two distinct genetic factors has remained unknown.
• The Pathological Gap: Recent studies identified amyloid fibrils composed of the C-terminal fragment of TMEM106B (TMEM106BFC) in the aging brain. However, it was unclear:
  1. How specific risk variants (like p.T185S in TMEM106B) drive fibril accumulation.
  2. Whether progranulin deficiency exacerbates this process.
  3. The precise subcellular location of these fibrils and whether they directly cause neurodegeneration.

2. Methodology

The authors employed a multi-modal approach combining human post-mortem proteomics, isogenic cellular models, transgenic mouse models, and advanced cryo-electron microscopy.

• Human Proteomics & Genetics:
  • Analyzed post-mortem brain tissue from the ROSMAP cohort (>1,000 samples) using peptide-level mass spectrometry (pQTL) to distinguish between full-length TMEM106B and its cleaved fibril core (TMEM106BFC).
  • Correlated genotypes (rs3173615 in TMEM106B and rs5848 in GRN) with protein levels.
• Isogenic Cellular Models (iPSC-derived Neurons):
  • Used CRISPR/Cas9 to create isogenic human induced pluripotent stem cell (iPSC) lines differing only by the TMEM106B p.T185S variant or GRN status (WT, heterozygous KO, homozygous KO).
  • Developed a novel PLD3-TMEM106BFC chimera system. Since endogenous TMEM106BFC levels are low and hard to study, they fused the N-terminus of Phospholipase D3 (PLD3) to the C-terminus of TMEM106B. This forced efficient delivery of the fibril core into the lysosomal lumen, mimicking endogenous processing without the artifacts of full-length overexpression.
  • Used dynamic Stable Isotope Labeling by Amino acids in Cell culture (dSILAC) to measure protein half-lives.
• In Vivo Mouse Models:
  • Generated mice via intracerebroventricular injection of AAV9 encoding the PLD3-TMEM106BFC (T185) chimera.
  • Aged mice for 13 months to assess neuropathology, including pTDP-43 inclusions, neuroinflammation, and CSF biomarkers.
• Advanced Imaging (Cryo-ET & Cryo-CLEM):
  • Utilized Cryo-Correlative Light and Electron Microscopy (Cryo-CLEM) and Cryo-Electron Tomography (Cryo-ET) on live neurons, mouse brain lysosomes, and human patient brain lysosomes.
  • Performed subtomogram averaging to resolve the atomic structure of fibrils in situ.
  • Isolated lysosomes via density gradient centrifugation to confirm fibril localization.

3. Key Contributions

• Identification of the Molecular Intermediate: The study identifies the cleaved intra-lysosomal fibril core of TMEM106B (TMEM106BFC) as the convergent molecular intermediate for both TMEM106B and GRN risk variants.
• Mechanism of Risk Variant Action: Demonstrated that the TMEM106B p.T185 risk variant does not increase total protein levels but specifically slows the degradation rate of the fibril core, leading to its accumulation.
• Genetic Interaction Mechanism: Showed that progranulin (GRN) loss acts upstream by impairing lysosomal proteolytic capacity, which further reduces TMEM106BFC degradation. The two factors act additively to drive fibril burden.
• Subcellular Localization: Provided the first direct visual evidence that TMEM106B fibrils form inside the lysosomal lumen, distinct from other amyloids (like Tau or TDP-43) that typically aggregate in the cytoplasm before entering lysosomes.
• Pathogenic Consequence: Established that intra-lysosomal fibril accumulation is sufficient to cause lysosomal rupture, neuroinflammation, and TDP-43 pathology, driving neurodegeneration.

4. Key Results

• Variant Specificity: In human brains and isogenic neurons, the p.T185 risk allele significantly increased levels of TMEM106BFC but had no effect on full-length TMEM106B.
• Degradation Kinetics: The T185 variant extended the half-life of TMEM106BFC by approximately 50% compared to the protective S185 variant.
• Progranulin Interaction:
  • GRN knockout neurons showed increased TMEM106BFC accumulation.
  • The combination of GRN loss and the TMEM106B T185 variant resulted in the highest fibril core burden.
  • Exogenous recombinant progranulin (rhPGRN) rescued this phenotype, nearly eliminating TMEM106BFC accumulation.
• Fibril Formation & Localization:
  • In PLD3-TMEM106BFC expressing neurons and mice, fibrils were observed exclusively within lysosomes.
  • Cryo-ET confirmed fibrils were composed of TMEM106B (matching known singlet and doublet structures) and were located inside the lysosomal lumen.
• Neurodegeneration in Mice: Mice overexpressing the fibril core developed:
  • Intra-lysosomal fibrils.
  • Elevated p62 (marker of impaired autophagy/lysosomal damage).
  • Microglial activation (CD68/IBA1).
  • pTDP-43 inclusions (a hallmark of FTLD-TDP), suggesting TMEM106B fibrils drive secondary proteinopathy.
  • Elevated CSF Neurofilament Light (NfL), indicating active neurodegeneration.
• Human Pathology:
  • FTLD-GRN patients had significantly higher insoluble TMEM106BFC than sporadic FTLD.
  • Cryo-ET of human FTLD brain lysosomes revealed intra-lysosomal fibrils.
  • Lysosomal Rupture: In FTLD-GRN cases, fibrils were observed protruding through ruptured lysosomal membranes, a phenomenon less common in sporadic cases. This suggests that excessive fibril growth physically breaches the lysosome.

5. Significance

• Unified Mechanism: This paper resolves a long-standing mystery in neurodegeneration genetics by showing how GRN and TMEM106B converge on a single pathway: the failure to degrade TMEM106BFC within the lysosome.
• Therapeutic Target: The findings suggest that enhancing lysosomal degradation or restoring progranulin levels could reduce TMEM106B fibril burden. This supports ongoing clinical trials for progranulin restoration in FTLD-GRN and suggests potential broader applicability to other neurodegenerative diseases where TMEM106B variants are risk factors.
• Novel Pathogenic Model: It proposes a "feed-forward" cycle where intra-lysosomal fibrils cause mechanical stress, leading to lysosomal rupture. This rupture releases toxic fibrils into the cytoplasm, impairing the degradation of other proteins (like TDP-43) and spreading pathology to neighboring cells.
• Structural Biology: The study confirms that TMEM106B fibrils can form and persist within the harsh environment of the lysosome, challenging previous assumptions about amyloid formation sites.

In summary, the study establishes that intra-lysosomal TMEM106B fibrillization is a primary driver of neurodegeneration, regulated by the interplay of TMEM106B coding variants and GRN levels, and offers a clear mechanistic target for therapeutic intervention.